Shape Therapeutics Prepares for Major Presentations at ESGCT Congress
Shape Therapeutics to Present at ESGCT Congress
Shape Therapeutics, a key player in RNA-based gene therapy, is excited to announce that it has two oral presentations accepted for the European Society of Gene and Cell Therapy (ESGCT) 32nd Congress. This significant event will take place in Seville, Spain, and offers an opportunity for researchers and professionals to engage with the latest advancements in gene therapy.
Details of the Upcoming Presentations
The first presentation is entitled Engineered AAV5 capsid SHP-DB1 efficiently targets the NHP brain after intravenous injection and transduces over 95% of neurons in the Parkinson's disease-critical substantia nigra. This talk will be given by Dr. Adrian Briggs from Shape Therapeutics. It's scheduled for Tuesday, October 7, during the session titled Session 2B from 5:00 PM to 7:30 PM CT, in Room Parallel B.
A Focus on Parkinson's Disease
The second presentation, titled Targeted Knockdown of Alpha Synuclein in the Brain Supports the Therapeutic Development of SHP-201 for Parkinson's Disease, features Dr. Leah Helton. This presentation will take place on Friday, October 10, during Session 12c: Gene Editing III: Technology & Applications, from 11:00 AM to 1:00 PM CT, located in Room Parallel C. Both sessions highlight the company's innovative approaches to tackling neurologic diseases, particularly Parkinson's disease.
Innovations in Gene Therapy
Shape Therapeutics is at the forefront of leveraging artificial intelligence to create cutting-edge payload, delivery, and manufacturing technologies for gene therapy. Their advancements aim to broaden the accessibility of genetic medicines and tackle previously hard-to-reach tissues by improving AAV capsid design.
About Shape Therapeutics
The company, based in Seattle, is pushing the boundaries of gene therapy through a robust pipeline that emphasizes RNA-targeting therapies. Shape's technologies are changing the landscape of how genetic disorders are treated, paving the way for advanced therapeutics that can improve lives.
Contact and More Information
For inquiries, reach out to Shape Therapeutics at info@shapetx.com. The company also maintains an active presence on LinkedIn, providing updates on their latest projects and developments.
Frequently Asked Questions
What is the significance of the ESGCT Congress?
The ESGCT Congress is a premier event that gathers leaders in gene and cell therapy to share research, innovations, and network for future collaborations.
Who will present at the congress?
Dr. Adrian Briggs and Dr. Leah Helton from Shape Therapeutics will present their respective research focused on Parkinson's disease.
What topics will be covered in the presentations?
The presentations will discuss advancements in targeting therapies for diseases like Parkinson's through innovative AAV technology.
How is Shape Therapeutics contributing to gene therapy?
Shape Therapeutics is advancing gene therapy by developing novel technologies that enhance delivery and efficacy of genetic medicines.
Where is Shape Therapeutics located?
Shape Therapeutics is headquartered in Seattle, Washington, focusing on cutting-edge research and therapeutic development.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
